metastatic colorectal cancer
Oncology · 2010–2017
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Jul 2017 | Recommended with restriction | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Nov 2016 | Not recommended | input received |
| cetuximab First-line treatment of patients with K-RAS wild-type metastatic colorectal cancer in combination with chemotherapy (FOLFIRI or FOLFOX). | Mar 2010 | Not recommended | no section in document |
What the PBS pays
$52M in government benefit over 2024–25, across 22,362 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| cetuximab | $42.5M |
| trifluridine with tipiracil | $9.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| guidance on the use of capecitabine and tegafurGuidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | recommended | 2003-05 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.